A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins

Simply Wall St.

Apr 02

Tarsus Pharmaceuticals (TARS) has drawn fresh attention after dosing the first participant in its Phase 2 Calliope trial of TP-05, an oral candidate aimed at preventing Lyme disease by killing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2624522801"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624522801\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624522801?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-04-02 11:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624522801","market":"nz","top_or_hot":-1,"title":"A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins","media":"Simply Wall St.","content":"<div>\n<p>Tarsus Pharmaceuticals (TARS) has drawn fresh attention after dosing the first participant in its Phase 2 Calliope trial of TP-05, an oral candidate aimed at preventing Lyme disease by killing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/a-look-at-tarsus-pharmaceuticals-tars-valuation-after-tp-05\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Tarsus Pharmaceuticals (TARS) Valuation After TP-05 Phase 2 Lyme Disease Trial Begins\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-02 11:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/a-look-at-tarsus-pharmaceuticals-tars-valuation-after-tp-05><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tarsus Pharmaceuticals (TARS) has drawn fresh attention after dosing the first participant in its Phase 2 Calliope trial of TP-05, an oral candidate aimed at preventing Lyme disease by killing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/a-look-at-tarsus-pharmaceuticals-tars-valuation-after-tp-05\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/a-look-at-tarsus-pharmaceuticals-tars-valuation-after-tp-05","article_id":"2624522801","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/a-look-at-tarsus-pharmaceuticals-tars-valuation-after-tp-05","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624522801","pubTimestamp":1775100937,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Tarsus Pharmaceuticals (TARS) has drawn fresh attention after dosing the first participant in its Phase 2 Calliope trial of TP-05, an oral candidate aimed at preventing Lyme disease by killing infected ticks.\nSee our latest analysis for Tarsus Pharmaceuticals.\nThe recent TP-05 progress and TP-03 milestone in China come as the share price sits at US$70.22, with a 7 day share price return of 4.9% but a 90 day share price return showing a 14.2% decline. The 1 year total shareholder return of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TARS":"Tarsus Pharmaceuticals, Inc."},"translate_title":"TP-05 2期莱姆病试验开始后Tarsus Pharmaceuticals(TARS)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TARS":1.5},"content_text":"Tarsus Pharmaceuticals (TARS) has drawn fresh attention after dosing the first participant in its Phase 2 Calliope trial of TP-05, an oral candidate aimed at preventing Lyme disease by killing infected ticks. See our latest analysis for Tarsus Pharmaceuticals. The recent TP-05 progress and TP-03 milestone in China come as the share price sits at US$70.22, with a 7 day share price return of 4.9% but a 90 day share price return showing a 14.2% decline. The 1 year total shareholder return of 36.4% and very large 3 year total shareholder return highlight how momentum has cooled after a very strong multi year run. If you are looking beyond a single biotech story, this could be a good moment to broaden your watchlist with 33 healthcare AI stocks With a commercial eye care product, growing revenue and a loss making income line, plus a share price well off its recent highs yet still far above where it was three years ago, is Tarsus now a potential opportunity, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 19.7% Undervalued At a last close of $70.22 versus a narrative fair value of $87.50, the most followed view sees meaningful upside already built into the story.  Expanded market access and international regulatory initiatives support top line growth, margin stability, and greater long term global revenue diversification. Strong demand from patient awareness and favorable demographic trends drive sustainable revenue expansion and reduce concentration risk through multi product pipeline development.  Read the complete narrative. Want to see what sits behind that confidence in higher margins and a bigger revenue base? The narrative leans heavily on future earnings power and a richer profit profile. Curious which growth, margin and valuation assumptions have to line up for $87.50 to make sense. Result: Fair Value of $87.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on XDEMVY maintaining strong uptake, while high SG&A and revenue concentration risk do not erode the path to those healthier margins. Find out about the key risks to this Tarsus Pharmaceuticals narrative. Another View: What The Sales Multiple Is Telling You While the narrative fair value points to meaningful upside, the current P/S ratio of 6.6x paints a more cautious picture. It is richer than the US pharmaceuticals industry average of 4.6x, yet below the peer average of 16.1x and close to a fair ratio of 6.9x, which suggests less obvious mispricing and more balanced risk. So the key question is whether the tension lies between growth expectations and what you are willing to pay for every dollar of revenue. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:TARS P/S Ratio as at Apr 2026Next Steps Mixed signals so far, with both risks and rewards in focus. Check the data now and weigh up the 3 key rewards and 1 important warning sign. Looking for more investment ideas? If you stop with just one stock here, you could miss other opportunities that fit your style. Use the screener to actively stack your watchlist with ideas.  Target quality at a discount by scanning for companies flagged in the 63 high quality undervalued stocks that match your return and risk preferences. Prioritise resilience by searching for companies in the 65 resilient stocks with low risk scores that align with a steadier approach to compounding capital. Spot early potential by checking the screener containing 25 high quality undiscovered gems for businesses with solid fundamentals that are not yet widely followed.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tarsus Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}